EUR/USD
1.16263
-0.058%
Gold
4382.63
-0.430%
Oil
94.722
0.541%
USD/JPY
154.092
0.354%
GBP/USD
1.35362
-0.072%
GBP/JPY
208.587
0.300%
Real-time News
Algerian Foreign Ministry: Before making the decision today to sever diplomatic ties with the UAE, we had exhausted all means to maintain bilateral relations.On September 10th, Xiaomi Technology announced that the Xiaomi-Robotics-U0 embodied world model training framework and model weights have been fully open-sourced. This open-source release provides Xiaomi-Robotics-U0 model weights in 4B and 34B sizes, supporting various tasks such as embodied scene generation, embodied scene editing, single image generation, image editing, video generation, and image-text interleaved sequence generation, along with a corresponding training and inference framework, targeting research in world models, embodied intelligence, and robotics applications. We hope that by opening up the model and code, we can lower the technical threshold and accelerate the exploration and implementation of world model technology in real-world robotic scenarios.Russias attack on Ukraines Dnieper region hit a factory owned by the U.S. agricultural producer Bunge.The local mayor stated that Russias attack on Ukraines Dniprom hit a factory owned by the American agricultural giant Bunge.On September 10th, Novartis (NVS.N) major shareholders called for a board reshuffle to improve corporate governance. This followed a record drop in the companys stock price this week due to setbacks in consecutive trials. Major shareholder David Samra stated, "The past chairmen have been disappointing in their acquisitions, and the company needs to change the way it oversees transactions." He also urged Novartis Chairman Giovanni Caforio to take action. Samra said, "I think he needs to make changes at the board level. One of these changes should be improving the teams responsible for these transactions, because clearly their performance has been mediocre at best." On Tuesday, Novartiss $12 billion acquisition of an American company, Avidity, for a muscular dystrophy drug failed in late-stage research, causing the companys stock price to plummet by more than 10%, wiping out nearly $30 billion in market capitalization. This followed disappointing results for the heart drug pelacarsen the previous day.
